Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
13 Mar 2007 Symphogen and Biovitrum Initiate Phase 1 Clinical Trial with The First Recombinant Polyclonal Antibody to Enter Clinical Evaluation
13 Mar 2007 TopoTarget Executes Its Licensing Option for the Development of Zemab for Breast Cancer
13 Mar 2007 Protherics to receive £10 million milestone from AstraZeneca
13 Mar 2007 New Insights Into Novel Mechanisms of Action of Genmab's HuMax-EGFr
08 Mar 2007 MAT Biopharma Announced Today the Initiation of the Phase I/II Escalating Dose of Ferritarg P(R)
07 Mar 2007 Kyowa Hakko Kogyo Co., Ltd. Licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharmaceuticals in the US.
01 Mar 2007 XOMA and Takeda Expand Collaboration for Therapeutic Antibody Discovery and Development
28 Feb 2007 Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled Antibody for the Treatment of Hormone-Refractory Prostate Cancer
28 Feb 2007 Vaccinex Announces Antibody Development And Commercialization Alliance In Multiple Sclerosis And Oncology
28 Feb 2007 EvoGenix and Vegenics announce collaboration
28 Feb 2007 HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
27 Feb 2007 Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in Japan
24 Feb 2007 Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancer
23 Feb 2007 Significant Phase III Results with CIMZIA(TM) in Rheumatoid Arthritis
23 Feb 2007 New phase III study confirms positive outcome of Avastin in patients with advanced lung cancer
23 Feb 2007 Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
15 Feb 2007 Viventia Biotech provides update on cancer antibody clinical development programs
15 Feb 2007 Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C Infection
15 Feb 2007 DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platform
14 Feb 2007 GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B(R) in systemic lupus erythematosus
14 Feb 2007 Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
14 Feb 2007 Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement
13 Feb 2007 BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials for Anticoagulant TB-402
08 Feb 2007 Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
08 Feb 2007 Johnson & Johnson Psoriasis Drug CNTO 1275 Posts Mixed Results In Phase 2 Trial
07 Feb 2007 ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
06 Feb 2007 AstraZeneca Licenses Regeneron's Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies
06 Feb 2007 Merck KGaA Seeks Approval for Erbitux for Colorectal Cancer in Japan
06 Feb 2007 UCB Licenses BioWa's POTELLIGENT(R) Technology for use in Antibody Research and Development
03 Feb 2007 Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
02 Feb 2007 Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26
26 Jan 2007 Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
26 Jan 2007 Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion
25 Jan 2007 Lucentis receives approval in the European Union - the first drug to improve vision in patients with wet AMD, a leading cause of blindness
25 Jan 2007 Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal Antibody
25 Jan 2007 First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritis
24 Jan 2007 Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement
18 Jan 2007 XOMA and Schering-Plough Add New Programs to Antibody Collaboration
17 Jan 2007 Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis
17 Jan 2007 Oxford Biomedica Announces Publication Of Avian Transgenic Results In Leading U.S. Scientific Journal
17 Jan 2007 Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
16 Jan 2007 4- Antibody AG Closes CHF 17 Million Series A Financing, Bringing the Total Series A Financing to CHF 23 Million ($ 18.5Million)
13 Jan 2007 BioInvent enters collaboration with Genentech to develop and commercialize BioInvent´s proprietary antibody for the potential treatment of cardiovascular diseases
12 Jan 2007 Immuno-Biological Laboratories Co., Ltd. and Intellect Neurosciences, Inc. Enter into Humanized Monoclonal Antibodies Development Agreement for the Treatment of Alzheimer's Disease
11 Jan 2007 Organon and the Academic Medical Center jointly develop novel treatment of rheumatoid arthritis
11 Jan 2007 ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
10 Jan 2007 BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401) Enhanced Using Potelligent(TM) Technology
09 Jan 2007 Ablynx and Boehringer Ingelheim sign $265 million research and licensing agreement to develop new Alzheimer's treatments
09 Jan 2007 Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
09 Jan 2007 Seattle Genetics to Present at the JPMorgan Annual Healthcare Conference
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 701 - 750 of 1157

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics